US Bancorp DE Sells 623 Shares of Enovis Corporation $ENOV

US Bancorp DE decreased its position in shares of Enovis Corporation (NYSE:ENOV) by 3.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 18,408 shares of the company’s stock after selling 623 shares during the period. US Bancorp DE’s holdings in Enovis were worth $577,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ENOV. Farther Finance Advisors LLC grew its holdings in Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares in the last quarter. GAMMA Investing LLC grew its holdings in Enovis by 144.8% during the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after buying an additional 692 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Enovis by 57.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock worth $74,000 after buying an additional 725 shares in the last quarter. Cullen Frost Bankers Inc. bought a new stake in Enovis during the first quarter worth $198,000. Finally, McIlrath & Eck LLC grew its holdings in Enovis by 52.2% during the first quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock worth $202,000 after buying an additional 1,808 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

ENOV has been the subject of several recent research reports. UBS Group decreased their price target on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Evercore ISI decreased their price target on Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Wells Fargo & Company reduced their price objective on Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.00.

Enovis Stock Up 0.7%

Shares of NYSE ENOV opened at $31.41 on Monday. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The business’s fifty day moving average price is $30.87 and its 200-day moving average price is $31.53. The stock has a market capitalization of $1.80 billion, a PE ratio of -2.20 and a beta of 1.69.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The firm had revenue of $383.81 million for the quarter. On average, equities research analysts anticipate that Enovis Corporation will post 2.79 EPS for the current year.

Insider Activity

In other news, SVP Bradley J. Tandy purchased 3,200 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were purchased at an average price of $31.41 per share, with a total value of $100,512.00. Following the transaction, the senior vice president directly owned 43,515 shares of the company’s stock, valued at approximately $1,366,806.15. This represents a 7.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Damien Mcdonald acquired 6,457 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The shares were bought at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the acquisition, the chief executive officer directly owned 102,753 shares in the company, valued at $3,182,260.41. This represents a 6.71% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 12,157 shares of company stock valued at $374,760 in the last 90 days. Insiders own 2.70% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.